Payday came right on time for NPS Pharmaceuticals Inc. and recent acquirer Shire plc with FDA approval of Natpara, a recombinant human parathyroid hormone (PTH), as an adjunct to calcium and vitamin D to control hypocalcemia in patients with hypoparathyroidism.